Molsidomine and lipid metabolism.
A postmarketing surveillance study was carried out in 3,757 patients suffering from chronic stable angina pectoris or angina at rest and treated with molsidomine alone or in combination with other antianginal drugs. During the 12-month survey, there was a significant decrease of total cholesterol, triglycerides, apolipoprotein B and B/A1 ratio, but no change of apolipoprotein A1. These results indicate that further investigations should be undertaken to analyze the possible favorable effect of molsidomine on lipid metabolism.